Reimbursement Is More Than Passing Thought For Spine Firm In FDA Trials
This article was originally published in The Gray Sheet
Executive Summary
Non-fusion spinal implant maker Paradigm Spine decided to spend 15%-20% more than needed to satisfy FDA's data requirements in an ongoing pivotal trial for what the company hopes will be its first product on the U.S. market
You may also be interested in...
FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews
Routine sharing of data between FDA and CMS will be possible for the first time under a June 23 memorandum of understanding that could serve as a first step toward parallel reviews for marketing approval and Medicare coverage
FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews
Routine sharing of data between FDA and CMS will be possible for the first time under a June 23 memorandum of understanding that could serve as a first step toward parallel reviews for marketing approval and Medicare coverage
Expectations For Artificial Disc Trials Challenge Market Hopefuls
Completing a pivotal trial may be the biggest challenge developers of artificial discs face as the market for the devices gets more crowded, say consultants